Roche KRAS G12C Inhibitor Extends Survival in Phase 3 KRAS-Mutant NSCLC Trial

The phase 3 study randomized patients with advanced KRAS G12C-mutant NSCLC who progressed after platinum chemotherapy and PD-1 inhibitors. Primary endpoint was overall survival, with progression-free survival and objective response rate as key secondaries. The trial demonstrated a 4.1-month absolute survival gain and 36% relative risk reduction, establishing the agent as a potential new standard for this molecular subset that comprises roughly 13% of lung adenocarcinomas.

Context from prior agents shows this result exceeds the 2-3 month gains seen with sotorasib and adagrasib in similar populations, likely due to improved selectivity and combination potential with immunotherapy backbones. Real-world data from flatiron registries indicate KRAS G12C patients currently cycle through 2.8 lines of therapy with median survival under 14 months, underscoring the clinical gap.

Regulatory filings are expected in the US and EU by late 2026. Questions remain about intracranial activity and resistance mechanisms, which will require dedicated cohorts in ongoing basket trials. Biomarker-driven sequencing strategies may shift if this agent moves into first-line settings.